top of page

2022 Rome Action Plan on Paediatric HIV & TB

IMPAACT

HIV MEDICINES FOR CHILDREN

IMPAACT commits to:

222. Determine dosing and safety of DTG dispersible tablets in newborns by third quarter 2024

223. Determine safety, dosing, and acceptability of long-acting injectable ART with cabotegravir and rilpivirine in adolescents by second quarter of 2024 and children over age 2 years by second quarter of 2024.

224. IMPAACT to collaborate with GAP-f partners and appropriate research networks to implement a platform trial to assess innovative options to deliver postnatal prophylaxis

Updates

 - 

bottom of page